Trv Gp Vi LLC Takes Position in Tango Therapeutics, Inc. $TNGX

Key Points

• Trv Gp Vi LLC bought 194,174 shares of Tango Therapeutics, representing approximately 0.13% of the company and 2.6% of the firm’s portfolio. Institutional investors and hedge funds collectively own 78.99% of TNGX.
• Analyst sentiment remains generally positive, with 13 Buy ratings, two Holds and one Sell. The stock has a consensus rating of “Moderate Buy” and an average price target of $43.46.
• TNGX opened at $25.44, versus a 52-week range of $6.25 to $34.39. Tango reported a quarterly loss of $0.37 per share, missing the $0.32 consensus estimate, while analysts expect a full-year loss of $1.36 per share.

Trv Gp Vi LLC bought a new stake in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 194,174 shares of the company's stock, valued at approximately $6,069,879,000. Tango Therapeutics makes up about 2.6% of Trv Gp Vi LLC's holdings, making the stock its 4th largest position. Trv Gp Vi LLC owned about 0.13% of Tango Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of TNGX. Global Retirement Partners LLC purchased a new position in Tango Therapeutics in the 4th quarter valued at about $35,000. Dynamic Technology Lab Private Ltd raised its holdings in shares of Tango Therapeutics by 139.7% during the first quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company's stock valued at $35,000 after acquiring an additional 15,037 shares during the last quarter. Legal & General Group Plc lifted its position in shares of Tango Therapeutics by 30.7% in the second quarter. Legal & General Group Plc now owns 6,985 shares of the company's stock valued at $36,000 after acquiring an additional 1,640 shares in the last quarter. ANTIPODES PARTNERS Ltd acquired a new stake in Tango Therapeutics during the 4th quarter worth $40,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Tango Therapeutics by 148,800.0% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,467 shares of the company's stock valued at $40,000 after acquiring an additional 4,464 shares in the last quarter. Institutional investors and hedge funds own 78.99% of the company's stock.

Insider Activity at Tango Therapeutics

In related news, insider Adam Crystal sold 27,000 shares of the stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $29.59, for a total value of $798,930.00. Following the transaction, the insider owned 115,743 shares of the company's stock, valued at $3,424,835.37. This represents a 18.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 6.50% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Jefferies Financial Group raised shares of Tango Therapeutics from a "hold" rating to a "buy" rating and lifted their target price for the stock from $27.00 to $60.00 in a research note on Thursday, June 25th. Raymond James Financial lowered shares of Tango Therapeutics to a "hold" rating in a research note on Thursday, June 25th. Canaccord Genuity Group upped their target price on shares of Tango Therapeutics from $42.00 to $46.00 and gave the stock a "buy" rating in a research note on Monday, June 29th. Leerink Partners increased their target price on shares of Tango Therapeutics from $55.00 to $69.00 and gave the stock an "outperform" rating in a report on Monday, June 8th. Finally, Wall Street Zen cut shares of Tango Therapeutics from a "sell" rating to a "strong sell" rating in a research report on Saturday. Thirteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $43.46.

Tango Therapeutics Stock Performance

Shares of Tango Therapeutics stock opened at $25.44 on Wednesday. Tango Therapeutics, Inc. has a one year low of $6.25 and a one year high of $34.39. The company has a market cap of $4.29 billion, a PE ratio of -29.93 and a beta of 1.16. The business has a 50-day simple moving average of $28.69 and a 200-day simple moving average of $22.51.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.05). On average, sell-side analysts predict that Tango Therapeutics, Inc. will post -1.36 earnings per share for the current fiscal year.

Tango Therapeutics Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company's lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source